Pharmacogenetics of asthma

British Journal of Clinical Pharmacology

Volumn 53, Issue 1, 2002, Pages 3-15

  Fenech, A ^a   Hall, I P ^b  

^a UNIVERSITY OF MALTA   (Malta)

^b C Floor   (Malta)

Author keywords

5 lipoxygenase; Asthma; Pharmacogenetics; Polymorphism; 2 adrenoceptor

Indexed keywords

AMINO ACID; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ATRELEUTON; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CATECHOL METHYLTRANSFERASE; CYCLIC AMP; CYTOCHROME P450 1A2; FENOTEROL; FORMOTEROL; GLUCOCORTICOID RECEPTOR; GLUCORECEPTOR; IMMUNOGLOBULIN E; ISOPRENALINE; LEUKOTRIENE; LEUKOTRIENE C4 SYNTHASE; MONTELUKAST; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; PEPTIDOLEUKOTRIENE; PHOSPHODIESTERASE; PRANLUKAST; SALBUTAMOL; SALMETEROL; TERBUTALINE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

AIRWAY; ARTICLE; ASTHMA; DESENSITIZATION; DNA FLANKING REGION; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HUMAN; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; START CODON;

AMINO ACID SEQUENCE; ANIMALS; ASTHMA; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2; VARIATION (GENETICS);

EID: 0036164899     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01509.x     Document Type: Article

References (101)

1. The pathology of asthma
2. Bronchial hyperresponsiveness: What causes twitchy airways?
3. Pharmacogenetics of asthma
4. Asthma, atopy, and genetic linkage
5. The genetics of asthma. Candidate gene approaches: Gene-environmental interactions
6. Linkage and candidate gene studies in asthma
7. The alliance of genes and environment in asthma and allergy
8. Is there a specific phenotype for asthma?
9. Determinants and regulating processes in bronchial hyperreactivity
10. Control of cyclic AMP levels in primary cultures of human tracheal smooth muscle cells
11. Pharmacology and molecular biology of adrenergic receptors
12. β-adrenergic agonists regulate KCa channels in airway smooth muscle by cAMP-dependent and -independent mechanisms
13. 2-adrenoceptor messenger RNA in human and rat lung using in situ hybridization: Correlation with receptor autoradiography
14. Mechanisms of β-adrenergic receptor regulation in lungs and its implications for physiological responses
15. Modulation of neurotransmission in airways
16. β-agonists
17. 2-adrenergic receptor: A protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor
18. 2-adrenergic receptor in normal and asthmatic subjects
19. 2-adrenergic receptor and asthma
20. 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitasation in moderately severe stable asthmatics
21. 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells
22. 2-adrenergic receptor structure
23. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties
24. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor
25. 2-adrenergic receptor gene restriction fragment length polymorphism and bronchial asthma
26. 2-adrenoceptor polymorphisms and asthma
27. 2-adrenergic receptor gene
28. 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness
29. 2 adrenergic receptor expression in human airway smooth muscle
30. β2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population
31. 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype
32. 2-adrenergic receptor polymorphism at amino acid 16 as a risk factor for bronchial hyperresponsiveness
33. 2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma
34. 2-adrenergic receptor on albuterol bronchodilator pharmacodynanucs
35. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing
36. 2-agonist therapy in asthma
37. Effects of genetic polymorphism on ex vivo and in vivo function of β2-adrenoceptors in asthmatic patients
38. Association of Glu 27 β-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects
39. 2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families
40. 2-adrenoceptor with reported childhood asthma: Population based study
41. 2-adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma
42. 2-adrenoceptor (ADRB2) haplotypes. A population study
43. Human liver catechol-O-methyltransferase pharmacogenetics
44. Leukotrienes: Fediators of immediate hypersensitivity reactions and inflammation
45. Leukotrienes as a target in asthma therapy
46. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis
47. Leukotrienes in asthma and rhinitis
48. Profound overexpression of leukotriene C4 synthase in bronchial biopsies from aspirin intolerant asthmatic patients
49. Leukotriene antagonists and synthesis inhibitors
50. Characterization of the human 5-lipoxygenase gene
51. Characterization of the human 5-lipoxygenase gene promoter
52. Pharmacogenctics of the 5-lipoxygenase pathway in asthma
53. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription
54. Molecular cloning of the gene for human leukotriene C4 synthase. Organization, nucleotide sequence, and chromosomal localization to 5q35
55. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma
56. Characterization of the human cysteinyl leukotriene CysLT1 receptor
57. Characterization of the human cysteinyl leukotriene 2 receptor
58. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment
59. Genetic variations in the 5-lipoxygenase core promoter
60. Mechanisms of action of glucocorticoids in asthma
61. Glucocorticoids: Mechanisms of action and anti-inflammatory potential in asthma
62. 2-adrenergic receptor transcription in human lung
63. Glucocorticoid treatment decreases muscarinic receptor expression in canine airway smooth muscle
64. In vivo glucocorticoids decrease expression of muscarinic receptors in airway smooth muscle
65. Glucocorticoid-resistant asthma: Pathogenesis and clinical implications for management
66. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma
67. The glucocorticoid receptor gene as a candidate for gene therapy in asthma
68. Antitumor promotion and antiinflammation: Down-modulation of AP-1 Fos activity by glucocorticoid hormone
69. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors
70. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance
71. A mutation of the glucocorticoid receptor in primary cortisol resistance
72. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo
73. Lack of association between live polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance
74. Chemical mutational analysis of the human glucocorticoid receptor cDNA in glucocorticoid-resistant bronchial asthma
75. PDE isoenzymes as targets for anti-asthma drugs
76. Characterization of five different proteins produced by alternatively spliced mRNAs flora the human cAMP-specific phosphodiesterase PDE4D gene
77. Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline
78. Phosphodiesterase inhibition and theophylline
79. Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease
80. Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes
81. Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment
82. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans
83. The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A
84. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver
85. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation
86. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population
87. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis
88. Phenotypic polymorphism and gender-related differences of CYPIA2 activity in a Chinese population
89. Phenotyping of CYPIA2 in Japanese population by analysis of caffeine urinary metabolites: Absence of mutation prescribing the phenotype in the CYP1A2 gene
90. Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population
91. Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: Lack of a polymorphism in CYP1A2 in Caucasians
92. Functional significance of a C - > A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
93. Genetic polymorphism in the 5′-flanking region of human CYPIA2 gene: Effect on the CYP1A2 inducibility in humans
94. Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia
95. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4
96. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism
97. Prejunctional inhibitory muscarinic receptors on cholinergic nerves in human and guinea pig airways
98. Muscarinic receptor subtypes in airways
99. Inflammatory and contractile agents sensitize specific adenylyl cyclase isoforms in human airway smooth muscle
100. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung
101. Pharmacogenetics and the practice of medicine